PPIDT00424
Drug Information
| Name | Tirzepatide |
|---|---|
| Sequence | YXEGTFTSDYSIXLDKIAQKAFVQWLIAGGPSSGAPPPS |
| DrugBank_ID | DB15171 |
| Type | biotech |
| Indication | Tirzepatide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus or for the chronic weight management for adult patients that are obese or overweight with at least one weight-related comorbid condition such as hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea, or cardiovascular disease). [L41815,L44376,L48761] In Europe, it may be used as monotherapy or in combination with other drugs used to treat diabetes.[L44376] This drug has not been studied in patients with a history of pancreatitis. Tirzepatide is not indicated for use in patients with type 1 diabetes mellitus.[L41815] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection, solution | Subcutaneous |
10 mg/0.5mL
|
| Injection, solution | Subcutaneous |
10 mg
|
| Injection, solution | Subcutaneous |
10 mg/dose
|
| Injection, solution | Subcutaneous |
12.5 mg/dose
|
| Injection, solution | Subcutaneous |
12.5 mg/0.5mL
|
| Injection, solution | Subcutaneous |
12.5 mg
|
| Injection, solution | Subcutaneous |
15 mg
|
| Injection, solution | Subcutaneous |
15 mg/0.5mL
|
| Injection, solution | Subcutaneous |
15 mg/dose
|
| Injection, solution | Subcutaneous |
2.5 mg/dose
|
| Injection, solution | Subcutaneous |
2.5 mg
|
| Injection, solution | Subcutaneous |
2.5 mg/0.5mL
|
| Injection, solution | Subcutaneous |
5 mg/dose
|
| Injection, solution | Subcutaneous |
5 mg/0.5mL
|
| Injection, solution | Subcutaneous |
5 mg
|
| Injection, solution | Subcutaneous |
7.5 mg/0.5mL
|
| Injection, solution | Subcutaneous |
7.5 mg
|
| Injection, solution | Subcutaneous |
7.5 mg/dose
|
| Solution | Subcutaneous |
10 mg / 0.5 mL
|
| Solution | Subcutaneous |
12.5 mg / 0.5 mL
|
| Solution | Subcutaneous |
15 mg / 0.5 mL
|
| Solution | Subcutaneous |
2.5 mg / 0.5 mL
|
| Solution | Subcutaneous |
5 mg / 0.5 mL
|
| Solution | Subcutaneous |
7.5 mg / 0.5 mL
|
| Solution | Subcutaneous |
10 mg
|
| Solution | Subcutaneous |
12.5 mg
|
| Solution | Subcutaneous |
15 mg
|
| Solution | Subcutaneous |
2.5 mg
|
| Solution | Subcutaneous |
5 mg
|
| Solution | Subcutaneous |
7.5 mg
|
| Solution | Subcutaneous |
10 mg / 0.6 mL
|
| Solution | Subcutaneous |
12.5 mg / 0.6 mL
|
| Solution | Subcutaneous |
15 mg / 0.6 mL
|
| Solution | Subcutaneous |
2.5 mg / 0.6 mL
|
| Solution | Subcutaneous |
5 mg / 0.6 mL
|
| Solution | Subcutaneous |
7.5 mg / 0.6 mL
|
| — | — |
10 mg/dose
|
| — | — |
15 mg/dose
|
Target Information